Document is current
Any future updates will be listed below
-
Authors
Matsumoto, Toshihiko
Cho, Sien
Nakasya, Akio
Nagai, Hiroki
Satake, Hironaga
Yasui, Hisateru
- License Information
-
More Information
Article History
Received: 3 June 2024
Accepted: 25 November 2024
First Online: 3 December 2024
Declarations
:
: Toshihiko Matsumoto received research funding from Ono Pharmaceutical Co, Ltd and Sanofi Co, Ltd; honoraria from Bayer Co, Ltd, Bristol-Myers Squibb Co, Ltd, Chugai Pharmaceutical Co, Ltd, Daiichi Sankyo Co, Ltd, Eli Lilly Japan Co, Ltd, Merck Bio Pharma Co, Ltd, MSD Co, Ltd, Ono Pharmaceutical Co, Ltd, Sanofi Co, Ltd, Taiho Pharmaceutical Co, Ltd, Takeda Co, Ltd, Teijin Pharmaceutical Co, Ltd and Yakult Honsha Co, Ltd. Hironaga Satake received lecture fees from Chugai, Takeda, and Merck Biopharma. Shien Cho, Akio Nakasya, Hiroki Nagai and Hisateru Yasui have no conflict of interest.
: This study was performed in line with the principles of the Declaration of Helsinki. The study protocol was approved by the Institutional Review Board of Kobe City Medical Center General Hospital (approval no. zn230610).
: Informed consent was obtained from all patients as opt-out forms on the hospital website.
